低磷酸酯酶症在普通及特定患者人群中的患病率:系统综述
该系统综述纳入27篇文献,评估持续低碱性磷酸酶(ALP)活性人群中低磷酸酯酶症(HPP)的频率。低偏倚风险研究中,基因确诊HPP频率在普通临床人群为10.4-26.2%,风湿科人群为46.4-56.5%,骨质疏松人群为57.1-87.5%;普通人群总患病率可能为17.6-36.0/10万。未诊断HPP常被识别,提示对持续低ALP且伴标志性表现者应考虑HPP。
要点
- 持续低ALP患者中未诊断HPP常见,应主动筛查。
- 骨质疏松人群中基因确诊HPP频率达57.1-87.5%。
- 普通人群HPP患病率可能为17.6-36.0/10万。
核心结论
- 在ALP筛查研究中频繁识别出未诊断的HPP患者,强调筛查的重要性。
- 临床医生对持续低ALP且伴标志性表现的患者应考虑HPP诊断。
研究设计与样本
- 系统综述检索PubMed和Embase及手动搜索2015年1月1日至2025年9月29日的英文文献。
- 纳入报告或可枚举HPP或潜在HPP频率的普通及特定临床人群(如风湿科、内分泌科)任何年龄的观察性研究,共27篇符合纳入标准。
- 基于4项预设标准评估偏倚风险,HPP患病率从偏倚风险最低的普通临床人群研究中确定。
主要发现
- 在低偏倚风险(≥3项预设标准)研究中,持续低ALP的普通临床人群基因确诊HPP频率为10.4-26.2%。
- 风湿科人群基因确诊HPP频率为46.4-56.5%。
- 骨质疏松人群基因确诊HPP频率为57.1-87.5%。
- 基于3项符合全部4项标准的研究,普通人群HPP总患病率可能为17.6-36.0/10万。
关键数值与推荐
- 持续低ALP的普通临床人群基因确诊HPP频率10.4-26.2%(低偏倚风险研究)。
- 风湿科人群基因确诊HPP频率46.4-56.5%(低偏倚风险研究)。
- 骨质疏松人群基因确诊HPP频率57.1-87.5%(低偏倚风险研究)。
- 普通人群HPP患病率可能为17.6-36.0/10万(基于3项符合全部4项标准的研究)。
临床怎么用
- 对持续低ALP且伴HPP标志性表现的患者,应考虑HPP诊断并进行筛查。
- 在风湿科和骨质疏松患者中,持续低ALP时应警惕HPP可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Hypophosphatasia (HPP) has diverse manifestations overlapping other skeletal and rheumatic disorders. This systematic review assessed frequency of HPP in select and general clinical populations with persistently low alkaline phosphatase (ALP) activity. Undiagnosed HPP was frequently identified. Clinicians should consider HPP for patients with persistently low ALP and hallmark manifestations. BACKGROUND: Diagnosis of hypophosphatasia (HPP) can be missed owing to its rare disease status and heterogeneous manifestations that can overlap with other skeletal or rheumatic disorders. The objective of this systematic review was to assess the frequency of HPP among patients with persistently low alkaline phosphatase (ALP) activity and determine overall HPP prevalence in the general population. METHODS: English language articles published from January 1, 2015, to September 29, 2025, were identified in PubMed and Embase and through manual searching. Observational studies conducted in patients of any age from general and select clinical populations (e.g., rheumatology, endocrinology) were included if the frequency of HPP or potential HPP was reported or could be enumerated from results. Risk of bias was assessed based on 4 predefined criteria. HPP prevalence was determined from general clinical population studies with the lowest risk of bias. RESULTS: A total of 710 articles were retrieved; 27 met the inclusion criteria. The frequency of genetically confirmed HPP among patients with persistently low ALP activity in studies with low risk of bias (≥3 predefined criteria) was 10.4-26.2% in general clinical populations, 46.4-56.5% in rheumatology populations, and 57.1-87.5% in osteoporosis populations. The total prevalence of HPP in the general population may be 17.6-36.0 per 100,000 population based on 3 studies meeting all 4 criteria. CONCLUSION: Undiagnosed patients with HPP were frequently identified in studies of ALP screening, highlighting the importance of screening. Clinicians should consider a diagnosis of HPP for patients with persistently low ALP and hallmark manifestations.
引用
- Schäfer VS, Hinman J, Moss K, et al. Prevalence of hypophosphatasia in general and selected patient populations: a systematic review. Osteoporos Int. 2026. PMID: 42844428. doi:10.1007/s00198-026-08227-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。